Comparison
MGF (Mechano Growth Factor) vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
910463-68-2
Molecular weight
2867.2 g/mol
4113.6 g/mol
Half-life
0.1 h
165 h
Sequence
YQPPSTNKNTKSQRRKGSTFEERKmodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
4
of which in humans
0
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
5